This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halder, J. Articles by Sood, A. K. Search for Related Content PubMed PubMed Citation Articles by Halder, J. Articles by Sood, A. K.

Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma

Departments of ¹ Gynecologic Oncology, ² Experimental Diagnostic Imaging, Chemistry Section, ³ Experimental Therapeutics, and ⁴ Cancer Biology, The University of Texas M. D. Anderson Cancer Center, and ⁵ Department of Bioengineering and Division of Applied Physics, Rice University, Houston, Texas; ⁶ Discovery Biology, Novartis Institutes for BioMedical Research, Tsukuba, Ibaraki, Japan; and ⁷ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cheil General Hospital, Kwandong University College of Medicine, Seoul, South Korea

Requests for reprints: Anil K. Sood, Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030. Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood{at}mdanderson.org.

Focal adhesion kinase (FAK) overexpression is frequently found in ovarian and other cancers and is predictive of poor clinical outcome. In the current study, we characterized the biological and therapeutic effects of a novel FAK inhibitor, TAE226. Taxane-sensitive (SKOV3ip1 and HeyA8) and taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo therapy experiments using TAE226 alone and in combination with docetaxel. Assessment of cytotoxicity, cell proliferation [proliferating cell nuclear antigen (PCNA)], angiogenesis (CD31), and apoptosis (terminal nucleotidyl transferase–mediated nick end labeling) were done by immunohistochemistry and immunofluorescence. In vitro, TAE226 inhibited the phosphorylation of FAK at both Y397 and Y861 sites, inhibited cell growth in a time- and dose-dependent manner, and enhanced docetaxel-mediated growth inhibition by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell lines, respectively. In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in the HeyA8, SKOV3ip1, and HeyA8-MDR models (46–64%) compared with vehicle-treated controls. However, the greatest efficacy was observed with concomitant administration of TAE226 and docetaxel in all three models (85–97% reduction, all P values <0.01). In addition, TAE226 alone and in combination with chemotherapy significantly prolonged survival in tumor-bearing mice. Even in larger tumors, combination therapy with TAE226 and docetaxel resulted in tumor regression. The therapeutic efficacy was related to reduced pericyte coverage, induction of apoptosis of tumor-associated endothelial cells, and reduced microvessel density and tumor cell proliferation. The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma. [Cancer Res 2007;67(22):10976–83]

This article has been cited by other articles:

				K. Sakurama, K. Noma, M. Takaoka, Y. Tomono, N. Watanabe, S. Hatakeyama, O. Ohmori, S. Hirota, T. Motoki, Y. Shirakawa, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor Mol. Cancer Ther., January 1, 2009; 8(1): 127 - 134. [Abstract] [Full Text] [PDF]

				H. K. Gan and L. L. Siu Focal Adhesion Kinase as a Therapeutic Target in Cancer ASCO Educational Book, January 1, 2009; 2009(1): 130 - 136. [Abstract] [Full Text] [PDF]

				E. Behmoaram, K. Bijian, S. Jie, Y. Xu, A. Darnel, T. A. Bismar, and M. A. Alaoui-Jamali Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness Am. J. Pathol., November 1, 2008; 173(5): 1540 - 1550. [Abstract] [Full Text] [PDF]

				M. Iiizumi, S. Bandyopadhyay, S. K. Pai, M. Watabe, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, K. Saito, E. Furuta, et al. RhoC Promotes Metastasis via Activation of the Pyk2 Pathway in Prostate Cancer Cancer Res., September 15, 2008; 68(18): 7613 - 7620. [Abstract] [Full Text] [PDF]